Our milestones bringing significant value to the table

Milestones

06 January 2021
ANT01 PCT PATENT

filing based on totally new and unexpected clinical relevant discoveries by inventor and owner Erik Buntinx, MD

06 January 2021
15 April 2021
Patentability of ANT01

as indicated by received International Search Report

15 April 2021
01 July 2021
Connecting the ANeuroTech Executive Team

bringing together more than 250 years of top level expertise in CNS Drug Development

01 July 2021
10 September 2021
Submission of FDA Pre-IND

Meeting Request on ANT01 in Partial Responsive Depression (PRD)

10 September 2021
22 October 2021
FDA Grant on Pre-IND Meeting

on the submitted ANT01 ā“Pivotal Phase III Development Program in Partial Responsive Depression (PRD)

22 October 2021
19 January 2022
FDA GRANTED PIND MEETING

allowing ANT01 to enter Phase III

19 January 2022
22 February 2022
Mid 2022: Start FDA APPROVED ANT01

PIVOTAL PHASE III Development Program

22 February 2022
05 July 2022
Positive Feed-Back of FDA on ANT-01

Positive Feed-Back of FDA on ANT-01 Target Product Profile in Major Depression and Subjective Cognitive Decline.

05 July 2022
Mid 2028: FDA Market Authorisation Approval

(MAA) ANT01 in PRD

Scroll to Top